Progyny (NASDAQ: PGNY) reported Q2 EPS of $0.19, $0.11 better than the analyst estimate of $0.08. Revenue for the quarter came in at $128.7 million versus the consensus estimate of $129.31 million.

“Progyny had a solid second quarter, with our strong topline growth and ongoing margin expansion reflecting the resiliency of fertility and our ability to continue to successfully navigate the complexities in this environment,” said David Schlanger, Chief Executive Officer of Progyny. “The desire for fertility and family building solutions is high, and as employers continue to plan for the future by ensuring that their benefits programs meet the needs and expectations of their targeted workforce, we are seeing strong momentum with both new sales and client renewals.

“The factors that we believe are the most critical to our ongoing growth, as well as our ability to continue to create long-term, sustainable value – which include our industry-leading clinical outcomes, our extraordinarily high member satisfaction rates, and our high client retention rate – are all going extremely well, and we remain confident that all of the macro-forces that have been positively influencing our growth remain intact at this time.”

“Our profitability growth and margin expansion this quarter continue to demonstrate the efficiencies we have realized as we scale the business, as well as the favorable comparisons to the prior year period, which reflected the previously-reported impacts from COVID-19 on our volumes at that time,” said Mark Livingston, Progyny’s Chief Financial Officer.

For earnings history and earnings-related data on Progyny (PGNY) click here.